Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 9 of 23, showing 5 Applications out of 114 total, starting on record 41, ending on 45

# Protocol No Study Title Investigator(s) & Site(s)

41.

ECCT/21/07/02   TALIOS
    A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

42.

ECCT/22/10/03   ISSC
    A randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics, and efficacy of escalating doses of oral ivermectin in scabies infected children weighing 5 to less than 15 kilograms in Kenya   
Principal Investigator(s)
1. Eunice Akinyi Ouma
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital
 
View

43.

ECCT/21/05/05   The “EMPATHY” Trial
    A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19.       
Principal Investigator(s)
1. DR LUCAS OTIENO TINA
2. Dr. Bernhards Ragama Ogutu
3. Dr Deborah Chepngeno Langat
4. Dr Videlis Nduba Nduba
5. Dr Janet Oyieko
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. Kenyatta University Teaching Referral and Research Hospital (KUTRRH) (Nairobi City county)
3. Kenya Medical Research Institute/US Army Medical Research Directorate-Kenya-Kericho (Kericho county)
4. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
5. KEMRI-USAMRD-A, Kisumu Field Station (Kisumu county)
 
View

44.

ECCT/21/05/06   VAC52150EBL2010 ;Phase 2
    An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen   
Principal Investigator(s)
1. Prof. Omu Anzala Omu Anzala
Site(s) in Kenya
KAVI-institute of Clinical Research
 
View

45.

ECCT/21/05/03   Adapt Out COVID
    Adaptive Platform Treatment trial for Outpatients with COVID-19   
Principal Investigator(s)
1. Kawango Agot
Site(s) in Kenya
1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county)
2. KEMRI WALTER REED (Kericho county)
3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
4. Kenya Medical Research Institute (Kisumu county)
 
View